Cargando…
Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence
SIMPLE SUMMARY: Locoregional therapies such as surgical resection, liver transplantation, and ablative techniques are preferred for early-stage HCC management. However, 70–80% of patients report HCC recurrence within 5 years of curative treatment. During the initiation and establishment of carcinoge...
Autores principales: | Devan, Aswathy R., Nair, Bhagyalakshmi, Aryan, Manu Kanjoormana, Liju, Vijayastelar B., Koshy, Joel Joy, Mathew, Bijo, Valsan, Arun, Kim, Hoon, Nath, Lekshmi R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216348/ https://www.ncbi.nlm.nih.gov/pubmed/37345066 http://dx.doi.org/10.3390/cancers15102729 |
Ejemplares similares
-
Translational Phytomedicines against Cancer: Promise and Hurdles
por: Devan, Aswathy R, et al.
Publicado: (2023) -
Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma
por: Devan, Aswathy R., et al.
Publicado: (2021) -
Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma
por: Devan, Aswathy R, et al.
Publicado: (2022) -
Critical biomarkers of hepatocellular carcinoma in body fluids and gut microbiota
por: Nath, Lekshmi R, et al.
Publicado: (2021) -
Mucus targeting as a plausible approach to improve lung function in COVID-19 patients
por: Kumar, Sarath S., et al.
Publicado: (2021)